Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz "Taltz has long delivered effective treatment with a well-established safety profile that ...

Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment of ...

(RTTNews) - Eli Lilly and Company (LLY) on Monday said its new formulation of Taltz (ixekizumab), which was approved by the FDA in May this year, is being made available across the U.S. The company ...

INDIANAPOLIS, March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application ...

Please provide your email address to receive an email when new articles are posted on . A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier ...

Eli Lilly and Company LLY announced that the FDA has approved its psoriasis drug Taltz (ixekizumab) for a new indication. Taltz injection (80 mg/mL) is now approved for the treatment of adult patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Taltz injection for treating moderate-to-severe plaque psoriasis in adults who are ...

Eli Lilly has received USFDA nod for Taltz injection, to treat plaque psoriasis, which could pose as a competition to Sun Pharma's skin disease drug. Advisory Alert: It has come to our attention that ...

Eli Lilly and Company LLY announced that the FDA has approved a supplemental biologics license application (sBLA) for its psoriasis drug Taltz (ixekizumab). Taltz injection (80 mg/mL) is now approved ...

When it comes to immunology, every drug is chasing AbbVie’s megablockbuster Humira, which sits alone at the top. To get doctors to switch, drugmakers need some compelling data—and Eli Lilly thinks it ...